Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′-C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection-Reference-Cited by-同舟云学术

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′-C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

Published:2019-04-05 Issue:9 Volume:62 Page:4555-4570
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Guangyi¹,Dyatkina Natalia¹,Prhavc Marija¹^ORCID,Williams Caroline¹,Serebryany Vladimir¹,Hu Yujian²,Huang Yongfei²,Wan Jinqiao²,Wu Xiangyang²,Deval Jerome¹,Fung Amy¹,Jin Zhinan¹,Tan Hua¹,Shaw Kenneth¹,Kang Hyunsoon¹,Zhang Qingling¹,Tam Yuen¹,Stoycheva Antitsa¹^ORCID,Jekle Andreas¹,Smith David B.¹,Beigelman Leonid¹

Affiliation:

1. Janssen BioPharma, Inc., South San Francisco, California 94080, United States

2. Department of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00143

Reference45 articles.

1. WHO. HCV Fact Sheet, Oct 2017. http://www.who.int/mediacentre/factsheets/fs164/en/.

2. Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?